Media.Player

Controlled release formulations for the induction and proliferation of regulatory T cells

Detailed Technology Description

None

*Abstract

BackgroundThe absence of regulatory T cells (Treg) is a hallmark for a wide variety of disorders such as autoimmunity, dermatitis, periodontitis and even transplant rejection. A potential treatment option for these disorders is to increase local Treg numbers. Enhancing local numbers of Treg through in situ Treg expansion or induction could be a potential treatment option for these disorders.TechnologyInvestigators at the University of Pittsburgh have developed a synthetic formulation that provides controlled release of several cytokines and drugs that are known to induce Tregs. The Tregs induced with this method express the same cell markers as natural Tregs and are able to suppress na├¤ve T cell proliferation. In fact, this controlled release system induced FoxP3 Tregs in human cells in vitro.Application* Treat diseases and conditions where Tregs are depleted *Autoimmunity *Dermatitis *Periodontitis *Transplant rejectionAdvantages* Current methods of expanding Tregs are flawed as they are not Treg-specific and have many side effectsPCT Patent application filed

*Principal Investigator

Name: Siddharth Jhunjhunwala, Postdoctoral Fellow

Department:

Name: Steven Little, Assistant Professor

Department: Engr-Dept Chairperson's Office

Name: Giorgio Raimondi, PhD

Department: Med-Surgery

Name: Angus Thomson, Professor of Surgery and Mol. Gen. & Bio

Department: Med-Surgery

Country/Region

USA